Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CTSA | P10619 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30004417 | 0.84 | EGLN2 (0.64) | KMT2AMEN1L3MBTL1SMN1; SMN2GAA | |
| SCHEMBL8883000 | 0.83 | MEN1 (0.46) | KMT2AMEN1L3MBTL1MAPTCTSA | |
| SCHEMBL704947 | 0.82 | EGLN2 (0.64) | SMN1; SMN2MAPTGAACTSA | |
| SCHEMBL968780 | 0.82 | KMT2A (0.51) | KMT2AMEN1L3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL966224 | 0.82 | KMT2A (0.48) | KMT2AMEN1L3MBTL1MAPTRAB9A | |
| SCHEMBL8885345 | 0.81 | PTPN1 (0.48) | KMT2AMEN1L3MBTL1 | |
| SCHEMBL8883325 | 0.81 | MEN1 (0.50) | KMT2AMEN1L3MBTL1MAPTCTSA | |
| Hydrochloric Acid SCHEMBL8882297 | 0.81 | EGLN2 (0.62) | SMN1; SMN2MAPTGAACTSA | |
| SCHEMBL8883447 | 0.80 | PTPN1 (0.50) | KMT2AMEN1L3MBTL1 | |
| SCHEMBL964829 | 0.80 | PTPN1 (0.50) | KMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | FIBROGEN, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11680047-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| EP-2298301-B2 | MEDICAMENTS FOR TREATING ANEMIA ASSOCIATED WITH KIDNEY DISEASE | FIBROGEN INC (US) | 2022-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680047-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | KMT2A 1533/4885MEN1 3852/4885L3MBTL1 2062/4885 |
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | EPOR, HAMP, TFRC | KMT2A 1095/4885MEN1 3714/4885L3MBTL1 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.